Skip to main content
An official website of the United States government

pyruvate kinase inhibitor TLN-232

A synthetic cyclic heptapeptide with potential antineoplastic activity. Pyruvate kinase (PK) inhibitor TLN-232 targets pyruvate kinase M2 (M2PK), which may disrupt tumor cell anaerobic glycolysis. M2PK is a dimeric isoform of PK and the predominant PK isoform found in tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:CAP-232
TLN-232
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search